Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018
- PMID: 31883809
- DOI: 10.1016/j.vaccine.2019.11.074
Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018
Abstract
Introduction: The Advisory Committee on Immunization Practices (ACIP) recommends vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in persons ≥65 years of age. To date, few studies have assessed the safety of Tdap in this population. We aimed to summarize reports submitted to the Vaccine Adverse Event Reporting System (VAERS) following receipt of Tdap in this age group.
Methods: We searched for and analyzed U.S. VAERS reports of Tdap among individuals ≥65 years of age submitted from September 1, 2010 through December 31, 2018. We classified reports according to concurrent vaccination, seriousness, and outcome (death, non-death) and determined the frequency of reported adverse events (AEs). For serious reports, we reviewed available medical records. Data mining analyses were undertaken to detect disproportionality in reporting.
Results: VAERS received a total of 1,798 reports following Tdap, of which 104 (6%) were serious. The most common AEs were injection site erythema (26%; n = 468), injection site pain (19%; n = 335), injection site swelling (18%; n = 329), and erythema (18%; n = 321). We identified seven deaths; none were attributed to Tdap. Among serious non-death reports, nervous system disorders (35.1%; n = 34) and infections and infestations (n = 18.6%; n = 18) were most commonly reported. Data mining did not identify any vaccine-AE combination reported more frequently than expected.
Conclusions: We did not identify any new safety concern over nearly a decade of recommended Tdap use among adults ≥65 years of age. Findings from this post-marketing review are consistent with prior post-marketing observations and pre-licensure studies.
Keywords: Post-licensure surveillance; Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap); Vaccine Adverse Event Reporting System; Vaccine safety.
Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016.Vaccine. 2020 Sep 11;38(40):6291-6298. doi: 10.1016/j.vaccine.2020.07.039. Epub 2020 Jul 31. Vaccine. 2020. PMID: 32747215 Free PMC article. Review.
-
Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015.Vaccine. 2016 Apr 29;34(20):2349-53. doi: 10.1016/j.vaccine.2016.03.049. Epub 2016 Mar 22. Vaccine. 2016. PMID: 27013434 Free PMC article.
-
U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.Vaccine. 2013 Feb 27;31(10):1447-52. doi: 10.1016/j.vaccine.2012.10.097. Epub 2012 Nov 8. Vaccine. 2013. PMID: 23142308
-
Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.Vaccine. 2011 Nov 21;29(50):9404-8. doi: 10.1016/j.vaccine.2011.05.100. Epub 2011 Sep 13. Vaccine. 2011. PMID: 21920404
-
Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2008 May 30;57(RR-4):1-51. MMWR Recomm Rep. 2008. PMID: 18509304 Review.
Cited by
-
Establishment of Safety Monitoring System for Vaccines Not Included in the National Immunization Program in Korea.J Korean Med Sci. 2024 Feb 5;39(5):e45. doi: 10.3346/jkms.2024.39.e45. J Korean Med Sci. 2024. PMID: 38317446 Free PMC article.
-
Success of Current COVID-19 Vaccine Strategies vs. the Epitope Topology of SARS-CoV-2 Spike Protein-Receptor Binding Domain (RBD): A Computational Study of RBD Topology to Guide Future Vaccine Design.Vaccines (Basel). 2022 May 25;10(6):841. doi: 10.3390/vaccines10060841. Vaccines (Basel). 2022. PMID: 35746449 Free PMC article.
-
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.Lancet Infect Dis. 2022 Jun;22(6):802-812. doi: 10.1016/S1473-3099(22)00054-8. Epub 2022 Mar 7. Lancet Infect Dis. 2022. PMID: 35271805 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical